

REMARKS/ARGUMENTS

Claims 1-4 are amended; Claims 12-27 are new; upon entry of the Amendment Claims 1-27 will be pending.

Amended Claim 1 is supported, for example, at original Claim 1. Amended Claim 2 is supported, for example, at original Claims 2 and 1, the features of original Claim 1 now incorporated into Claim 2. Amended Claim 3 is supported, for example, original Claims 3 and 1, the features of original Claim 1 now incorporated into Claim 3. Amended Claim 4 is supported, for example, at original Claims 4 and 1, the features of original Claim 1 now incorporated into Claim 4. New Claims 12-27 are supported, for example, at original Claim 1 and at specification pages 15-17. No new matter is added.

Applicants thank Examiner Ho for indicating that Claims 2-3 would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The indication of allowable subject matter is truly appreciated.

The anticipation rejection of Claims 1 and 4 as being unpatentable in view of Cea is traversed. Cea discloses the following compound:





Fig. 1. Chemical structure of PPyD.

Cea's PPyD Compound has one oxadiazole ring:




In the compound of present Claim 1, having the general formula (1) shown below:



compound of present Claim 1 has two or three oxadiazole rings. This feature is not described or suggested by Cea, whose compound has one oxadiazole ring, as described above. Cea therefore cannot anticipate the compound of present Claim 1.

Claims 2 and 3 are amended to be independent claims that include the features of original Claim 1. Accordingly, as described at page 4 of the Official Action, Claims 2 and 3 are allowable.

In the compound of present Claim 4, having the general formula (1), reproduced here:



unsubstituted aromatic hydrocarbon group, an unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted condensation polycyclic aromatic group. Cea's compound PPyD, has a substituted aromatic heterocyclic group (e.g., a substituted pyridine ring) attached to the oxadiazole group. Accordingly, Cea does not describe or suggest the Ar group feature of present Claim 4.

Withdrawal of the anticipation rejection is requested.

Rejoinder of the withdrawn claims under M.P.E.P. § 821.04 is requested.

Applicants submit the present application is now in condition for allowance. Early notification to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, L.L.P.
Richard L. Treanor



Charles J. Andres, Jr., Ph.D.
Attorney of Record
Registration No. 57,537

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 07/09)